Sign in
Taking people in United StatesNo phase

Serration balloon versus standard balloon for leg arteries in critical limb ischemia

Compares Serranator with standard balloon angioplasty in critical limb ischemia.

Key facts

Who runs it
Cagent Vascular LLC
Where
New York, United StatesSee the 2 sites
Trial code
Registry title
Serrantor OCT Study
Status
Recruiting
People taking part
60 people, planned
Started
31 Oct 2024
Planned end
1 Jun 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Serranator PTA Serration Catheter
  • PTA (Standard of Care)
Record updated
18 May 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with severe poor blood flow in a leg, called critical limb ischemia, in arteries below the knee. It compares Serranator serration balloon angioplasty with standard balloon angioplasty (PTA).

Age
Older than 18 years (minimum age 19 Years).
Sex
All sexes can join.
Disease stage
Rutherford clinical category 4-6 in the leg being treated. This means severe disease, such as pain at rest, wounds or tissue loss.

Main reasons for not taking part

  • The record lists under exclusions: a new or returning narrowing (≥70%, no prior stent) or a full blockage.
  • The record lists under exclusions: the treated narrowing is in the arteries below the knee, down to the foot.
  • The record lists under exclusions: the artery size on imaging is between 2.0 and 5.0 mm.
  • The record lists under exclusions: the narrowed section is less than 220 mm long.

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Rutherford clinical category 4-6 of the target limb
  • Age of subjects is >18 years old
  • Patients has given informed consent to participate in this study

Who cannot take part

  • De novo or restenotic (without prior stent) stenosis (≥70%) or occlusion
  • Target lesion is in the BTK arteries, including below the knee popliteal, tibioperoneal trunk, tibial, peroneal, and pedal arteries
  • Angiographic visual estimated reference vessel diameter is between 2.0 and 5.0 mm
  • Lesion length less than 220 mm

Where in United States

  • Columbia UniversityNew York, United StatesContact: K DaltonTaking people
  • Weill Cornell MedicalNew York, United StatesContact: R ChuTaking people

About the trial

What the trial wants to find out

TA prospective randomized control trial to evaluate the serration angioplasty effect in BTK arteries with varying degrees of calcified plaque.

The 2 groups in the trial

  • SerrantorExisting treatment, for comparison

    Subjects randomized to the Serranator Arm of the study will be treated with the Serranator PTA Serration Balloon

    Treatment: Serranator PTA Serration Catheter

  • PTAExisting treatment, for comparison

    Subjects randomized to the PTA Arm of the study will be treated with a standard of care percutaneous transluminal angioplasty (PTA) balloon.

    Treatment: PTA (Standard of Care)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Serranator OCT: Understanding the Mechanism of Action of Serration Angioplasty by Serranator Versus Conventional Balloon Angioplasty for below-the Knee (BTK) Artery Disease Using Optical Coherence Tomography (OCT)
Plain-language title
Serration balloon versus standard balloon for leg arteries in critical limb ischemiaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
18 May 2025